Sign in

    Harry Jenq

    former Associate at JMP Securities

    Harry Jenq is a former Associate at JMP Securities, specializing in biotech and medtech equity research, with coverage including companies such as Zafgen. During his time at JMP Securities from 2015 to 2017, Jenq engaged in earnings call analysis and contributed to investment research within the life sciences sector. His career includes prior roles as Associate at Sanford C. Bernstein, Analyst at Millennium Management, and his current position as Managing Director at Perceptive Advisors since 2018. Jenq holds a Ph.D. in Biomedical Engineering from Harvard University and a B.A. in Molecular Biology from Princeton University, further supported by his expertise in financial analysis and securities research.

    Harry Jenq's questions to ZFGN leadership

    Harry Jenq's questions to ZFGN leadership • Q4 2015

    Question

    Harry Jenq, on behalf of JMP Securities, asked about hypothetical risk mitigation strategies for beloranib if it is confirmed to increase thrombotic events, such as patient subsetting or prophylactic medication, and how an overall benefit could be demonstrated.

    Answer

    CEO Tom Hughes outlined three primary strategies being considered: 1) enrolling low-risk patients with rigorous monitoring, 2) treating patients for thrombosis if abnormal values appear, or 3) administering prophylactic medication before starting treatment. He stated they would likely begin with a conservative approach to suppress risk and will provide updates after gaining clarity from the FDA.

    Ask Fintool Equity Research AI